GSK Partners with Hengrui Pharma to Develop Innovative Medicines

Deal News | Jul 28, 2025 | GSK PLC

GSK plc, a leading global biopharma company, has entered into significant agreements with Hengrui Pharma to develop up to 12 innovative medicines, including a promising PDE3/4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease (COPD). This strategic collaboration, valued at up to $12 billion, will see GSK make an upfront payment of $500 million to Hengrui Pharma and potentially provide further success-based payments. GSK has secured worldwide rights (excluding select Asian markets) to an exclusive license for the PDE3/4 inhibitor slated to enhance its existing portfolio while aiming to treat a broad spectrum of COPD. An additional 11 programs will undergo development by Hengrui Pharma through phase I trials, with GSK holding exclusive rights to advance and commercialize these breakthroughs globally, excluding certain regions. This partnership aligns with both companies' aspirations to leverage their respective expertise in disease biology, clinical capabilities, commercialization, and R&D, paving the way for expedited delivery of pioneering treatments worldwide.

Sectors

Pharmaceuticals
Biotechnology

Geography

United Kingdom – GSK, the primary entity in the article, is based in the United Kingdom.
China – Hengrui Pharma, involved in the collaboration, is based in China.
Global – The agreements have a worldwide impact, excluding certain Asian regions, emphasizing a global geographical scope.

Industry

Pharmaceuticals – The article discusses agreements to develop innovative medicines, indicating activity within the pharmaceutical industry.
Biotechnology – The focus on cutting-edge therapies and novel drug developments aligns the content with the biotechnology sector.

Financials

$500 million – The upfront payment GSK is making across agreements with Hengrui Pharma.
$12 billion – The potential total value of success-based payments for development, regulatory, and commercial milestones.
Royalties – Tiered royalties on net sales applicable globally, excluding mainland China, Hong Kong, Macau, and Taiwan.

Participants

Name	Role	Type	Description
GSK plc	Collaborating pharmaceutical company	Company	A global biopharma company focused on science, technology, and talent to advance disease prevention and treatment.
Hengrui Pharma	Collaborating pharmaceutical company	Company	An innovative pharmaceutical company dedicated to developing and commercializing high-quality medicines with a global R&D presence.
Tony Wood	Chief Scientific Officer at GSK	Person	An influential figure in driving GSK's strategic investments and pipeline expansions.
Frank Jiang	Chief Strategy Officer at Hengrui Pharma	Person	Plays a key role in Hengrui's strategic collaboration with GSK and the company's globalization efforts.